WebSep 12, 2024 · This phase I trial studies the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with … WebThe authors have designed a randomized phase III controlled study comparing the efficacy of gemcitabine and cisplatin, and dose-dense methotrexate, vinblastine ... before or after radical cystectomy. Higher toxicity regarding asthenia and gastrointestinal side effects along with a better bladder control rate were observed in the ...
Hematological side-effect profiles of individualized chemotherapy ...
WebApr 8, 2014 · GDP (gemcitabine, dexamethasone, cisplatin) This treatment cycle is repeated every 21 days. You will have 2 to 3 cycles and may continue up to 6 cycles. ... This can … WebFeb 10, 2024 · Update: On September 2, 2024, the Food and Drug Administration approved durvalumab in combination with gemcitabine and cisplatin for people with biliary tract cancer based on results from the TOPAZ-1 clinical trial. The approval is for adults with biliary tract cancer that has spread from the original site in the gallbladder or bile duct and … port of fujairah
Gemcitabine-cisplatin: a schedule finding study - PubMed
WebWhat are the Important Side Effects of Gemcitabine-Cisplatin? Inform the nurses immediately during infusion of Gemcitabine-Cisplatin if you Allergic reaction Gemcitabine-Cisplatin may rarely cause an being given. Signs of a reaction can include a rash, flushing or shortness of breath, swelling of your face or lips, feeling dizzy, having ... WebIt had no statistically significant differences in curative effects and adverse reactions. The RRs were 22% and 22%, respectively. One-year survival rates were 31% and 36%, respectively. What we have researched was Abraxane plus cisplatin and gemcitabine plus cisplatin, and their RRs were higher than ECOG 1594 clinical trials. WebFeb 1, 2024 · Appropriate studies have not been performed on the relationship of age to the effects of cisplatin injection in the pediatric population. Safety and efficacy have not been established. This medicine may increase the risk for serious ear or hearing problems in children younger that 5 years of age. port of fuerteventura